美多比星 | 64314-52-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 中文名称: 美多比星
• 英文名称: 4-demethoxydoxorubicin
• 英文别名: doxorubicin；4-demethoxyadriamycin；DOX；Medorubicin；(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione
• CAS: 64314-52-9
• 化学式: C₂₆H₂₇NO₁₀
• 分子量: 513.501
• InChiKey: XVXGYZFARCOVHS-BINOZUKVSA-N

物化性质

• 沸点：
  599.5°C (rough estimate)
• 密度：
  1.3763 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  37
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  197
• 氢给体数：
  6
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  (+)-3'-N-trifluoroacetyl-4-demethoxyadriamycin 生成 美多比星
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Anthracycline Derivatives For Treating Tumor Diseases
  申请人：Produkem Molekulares Design GmbH

  公开号：US20150252069A1

  公开（公告）日：2015-09-10

  The invention relates to compounds of the general formula (I) in which R 1 is a hydrogen atom, a hydroxy or methoxy group, a halogen atom, or an NO 2 group; R 2 is a hydrogen atom, a hydroxy or methoxy group, or an acyl or aroyl group; R 3 is hydrogen, trifluoroacetyl (C(═O)CF 3 ), or p-nitrobenzoyl (C(═O)PhNO 2 ), and in each case the wavy line represents both possible configurations of —OR 3 relative to the skeleton; Y is [C(═O)], [C(═N)—OH], [CH—OH], or [CH—NR 5 R 6 ] in the two possible stereoisomer arrangements, wherein R 5 and R 6 either each represent a hydrogen atom or a hydrogen atom and a trifluoroacetyl group (TFA); X=O, S, or NR, in which R=hydrogen or a C 1 to C 4 alkyl group; and R 4 is an unbranched or branched alkyl or heteroalkyl chain with a chain length of 1 to 19 elements, maximally 6 heteroatoms (O, N, S) being separated from one another in any combination by at least two carbon atoms. The invention further relates to, among others, methods for producing the compounds according to formula (I), to pharmaceutical compositions, to a pharmaceutical kit, and to the use thereof as a medicament for treating proliferative diseases or conditions, preferably cancer.

  本发明涉及通式(I)的化合物，其中R1是氢原子、羟基或甲氧基、卤素原子或NO2基团；R2是氢原子、羟基或甲氧基、酰基或芳酰基；R3是氢、三氟乙酰基(C(═O)CF3)或对硝基苯甲酰基(C(═O)PhNO2)，并且每次波浪线代表相对于骨架的—OR3的两种可能构型；Y是[C(═O)]、[C(═N)—OH]、[CH—OH]或[CH—NR5R6]，在两种可能的立体异构体排列中，其中R5和R6各自代表氢原子或氢原子和三氟乙酰基(TFA)基团；X=O、S或NR，其中R=氢或C1至C4烷基；R4是无分支或有分支的烷基或杂烷基链，链长为1至19个元素，最多6个杂原子(O、N、S)以任何组合彼此至少由两个碳原子隔开。本发明还涉及，其中包括，根据通式(I)的化合物的制备方法、药物组合物、药物套件及其作为药物用于治疗增生性疾病或状况，特别是癌症的用途。
• Daunosaminyl anthracyclinones and their use
  申请人：Societa' Farmaceutici Italia S.p.A.

  公开号：US04125607A1

  公开（公告）日：1978-11-14

  Disclosed is a class of novel daunosaminyl anthracyclinones which are useful in treating Sarcoma 180 ascites.

  公开了一类新型的多柔比星糖基蒽环酮，其可用于治疗Sarcoma 180腹水。
• Methods and compositions for the manufacture of C-3' and C-4' anthracycline antibiotics
  申请人：——

  公开号：US20020137694A1

  公开（公告）日：2002-09-26

  The present invention discloses new and novel substituted anthracyclines with modified alkyl-aromatic ring substitutions on the C-3′ of the sugar moiety or modified or unmodified alkyl-aromatic ring substitutions at the C-4′ of the sugar moiety. It also discloses novel methods for the preparation of sugar substrates and methods for the preparation of anthracycline antibiotics. These anthracycline analogs show high cytotoxicity in vitro against several tumor cell lines.

  本发明揭示了一种新的、具有改性烷基芳香环取代基的葡萄糖基团C-3'或改性或未改性烷基芳香环取代基的葡萄糖基团C-4'的新型替代蒽环素。它还揭示了制备糖基底物和蒽环素抗生素的新方法。这些蒽环素类似物在体外对多种肿瘤细胞系表现出高细胞毒性。
• [EN] BIS-ANTHRACYCLINES WITH HIGH ACTIVITY AGAINST DOXORUBICIN RESISTANT TUMORS<br/>[FR] BISANTHRACYCLINES PRESENTANT UNE FORTE ACTIVITE CONTRE DES TUMEURS RESISTANTES A LA DOXORUBICINE
  申请人：PRIEBE, Waldemar

  公开号：WO1997034612A1

  公开（公告）日：1997-09-25

  (EN) The present invention discloses new and novel bis-anthracyclines linked through the C-3' or C-4' saccharide portions. These compounds show high activity against two clinically relevant mechanisms of resistance. A novel approach of the invention produces compounds that are as active or more so than the parent compounds. Furthermore, the inventor's discovery is also for the design of effective DNA-binding bis-anthracyclines as well as anthracyclines mixed with other intercalators and groove binders.(FR) L'invention a pour objet de nouvelles bisanthracyclines liées par les parties saccharides C-3' ou C-4'. Ces composés présentent une forte activité contre deux mécanismes de résistance cliniquement importants. Un nouveau procédé permet de produire des composés qui sont au moins aussi actifs que les composés parents. En outre, l'invention concerne la conception de bisanthracyclines efficaces liant l'ADN et d'anthracyclines mélangées à d'autres intercalants et liants de sillon.

  该发明揭示了通过C-3'或C-4'糖分子部分连接的新型双蒽环素。这些化合物对两种临床相关的耐药机制表现出高活性。该发明的一种新方法可生产与原始化合物同样或更活跃的化合物。此外，该发明还用于设计有效的DNA结合双蒽环素以及与其他插入剂和槽结合剂混合的蒽环素。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。